Drug delivery as a primary design variable How delivery-led design is reshaping molecular engineering and downstream purification
The shift: delivery is no longer just a downstream consideration
Delivery decisions now shape the molecule
Drug delivery has traditionally been treated as a downstream consideration in biologics development, addressed after the molecule is defined and the process established. That model has shifted. Delivery is increasingly acting as a primary design variable, shaping not only how a therapy is administered, but how it is engineered, manufactured, and purified.
As a result, in many cases, delivery is a guiding principle that shapes the molecule from the outset. Choosing a delivery approach effectively commits a program to a specific model of use.
This reflects a broader shift in how therapies are conceived. Development is moving away from designing molecules in isolation and toward designing therapies around real-world use. Delivery is no longer an afterthought applied to a finished product but a defining feature of the product itself.
A long-acting therapy designed for chronic administration follows a fundamentally different development pathway from an acute intravenous treatment. A biologic intended for subcutaneous delivery in the home must meet different requirements than one administered in a clinical setting. These decisions cascade through clinical strategy, regulatory pathways, and commercial positioning.
Designing therapies around real-world use
Crucially, they also define the physical and functional properties of the molecule itself.
Today, developers are starting from a different question: how will this therapy be used in practice? Decisions around dosing frequency, route of administration, and site of care are being made earlier, often before lead optimization is complete.
The downstream consequence: purification is no longer platform-safe
This shift is driven by several converging forces. In chronic disease, treatment economics and patient adherence are critical. Extending half-life is a way to reduce dosing burden and align treatment with real-world use. At the same time, healthcare systems are under pressure to move care out of infusion centers and into outpatient or home settings, increasing the importance of subcutaneous delivery.
When delivery strategy changes the molecule, downstream processing becomes harder to predict and control. It doesn’t simply adapt, it is often fundamentally redefined. Binding interactions shift, and impurity profiles become more complex. This can include increased heterogeneity in fusion constructs, altered hydrodynamic behavior, and co-elution of structurally similar variants. These effects challenge conventional capture and polishing strategies, and established purification assumptions begin to break down.
Alongside these factors is a growing emphasis on patientcentric design. Administration time, injection burden, and device compatibility are now central considerations. Therapies are expected to fit into patients’ lives, not disrupt them.
For decades, platform purification approaches, particularly for monoclonal antibodies, have provided robustness and efficiency. But as delivery-driven formats emerge, those platforms are becoming less universally applicable. Fusion
astreabioseparations.com